Fig. 1.

Tumor response to bintrafusp alfa assessed by independent review. a Best change in sum of diameters and tumor mutation count. A threshold of 1% was used to characterize tumors as either PD-L1 positive (≥ 1%) or negative (< 1%) using an anti-PD-L1 antibody clone 73-10. One patient had non-evaluable PD-L1 expression. b Time to and duration of response. The upper dashed line represents progression at 20% increase in size of target lesions, and the lower dashed line represents the RECIST boundary for partial response at 30% decrease in size of target lesions. Six patients are not shown because they had no post-baseline assessments due to death within 6 weeks after starting treatment (n = 2), had no baseline and post-baseline target lesion measurement (n = 1), or due to other reasons (n = 3). ^aTumor mutation count data unavailable. NE not evaluable, PD progressive disease, PR partial response, SD stable disease